Jeffrey Melson Clarke, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, Box 31379 Med Ctr, Durham, NC 27710
Phone (919) 684-8111
Email address jeffrey.clarke@duke.edu
In Their Words

Education and Training

  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine, 2012 - 2013
  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine, 2011 - 2015
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine, 2008 - 2011
  • M.D., Indiana University, School of Medicine, 2008

Grants

Publications

Le, Xiuning, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, et al. “Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.” J Clin Oncol 40, no. 7 (March 1, 2022): 710–18. https://doi.org/10.1200/JCO.21.01323.

PMID
34843401
Full Text

Gupta, Anjali, Dongyu Zhang, Dejana Braithwaite, Shama D. Karanth, Tina D. Tailor, Jeffrey M. Clarke, and Tomi Akinyemiju. “Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB).” J Immunother 45, no. 2 (February 2022): 132–37. https://doi.org/10.1097/CJI.0000000000000400.

PMID
34747372
Full Text

Rottey, Sylvie, Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, et al. “Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.” Clin Cancer Res 28, no. 1 (January 1, 2022): 95–105. https://doi.org/10.1158/1078-0432.CCR-21-1181.

PMID
34615718
Full Text

Kao, Chester, Eric Powers, Yuan Wu, Michael B. Datto, Michelle F. Green, John H. Strickler, Neal E. Ready, Tian Zhang, and Jeffrey M. Clarke. “Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.” Clin Lung Cancer 22, no. 6 (November 2021): 500–509. https://doi.org/10.1016/j.cllc.2021.03.017.

PMID
33972172
Full Text

Clarke, Jeffrey M., Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara, D. Ross Camidge, Martin Dunbar, Silpa Nuthalapati, Minh H. Dinh, and Bruce A. Bach. “Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.” Lung Cancer 161 (November 2021): 180–88. https://doi.org/10.1016/j.lungcan.2021.09.004.

PMID
34607210
Full Text

Sidell, Douglas R., Karthik Balakrishnan, Simon R. Best, Karen Zur, Julia Buckingham, Alessandro De Alarcon, Fuad M. Baroody, et al. “Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.” Laryngoscope 131, no. 6 (June 2021): E1941–49. https://doi.org/10.1002/lary.29343.

PMID
33405268
Full Text

Dorry, Michael, Kevin Davidson, Rajesh Dash, Rachel Jug, Jeffrey M. Clarke, Andrew B. Nixon, and Kamran Mahmood. “Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis.” Transl Lung Cancer Res 10, no. 6 (June 2021): 2500–2508. https://doi.org/10.21037/tlcr-21-123.

PMID
34295657
Full Text

Deveaux, April E., Tyler A. Allen, Muthana Al Abo, Xiaodi Qin, Dadong Zhang, Brendon M. Patierno, Lin Gu, et al. “RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.” Lung Cancer 153 (March 2021): 90–98. https://doi.org/10.1016/j.lungcan.2021.01.015.

PMID
33465699
Full Text

Lee, Tristan, Jeffrey M. Clarke, Deepali Jain, Sendhilnathan Ramalingam, and Vishal Vashistha. “Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.” Cleve Clin J Med 88, no. 2 (February 1, 2021): 117–27. https://doi.org/10.3949/ccjm.88a.19148.

PMID
33526466
Full Text

Pages